Cover Image
市場調查報告書

Haemostatix Limited : 產品平台分析

Haemostatix Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 310653
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Haemostatix Limited : 產品平台分析 Haemostatix Limited - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 20 Pages
簡介

Haemostatix Ltd 是總公司設置於英國諾丁漢之生物科技企業,正在開發及商品化治療出血用新平台,及開發可治療手術、心臟外傷上出血及白血病患者出血所用的產品,同時也進行產品的臨床實驗。

本報告提供Haemostatix Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Haemostatix Limited的基本資料

  • Haemostatix Limited概要
  • 主要資訊
  • 企業資料

Haemostatix Limited:R&D概要

  • 主要的治療範圍

Haemostatix Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Haemostatix Limited:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Haemostatix Limited:藥物簡介

  • PeproStat
  • HaemoPlax
  • HXTC-901

Haemostatix Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

Haemostatix Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07506CDB

Summary

Global Markets Direct's, 'Haemostatix Limited - Product Pipeline Review - 2015', provides an overview of the Haemostatix Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Haemostatix Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Haemostatix Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Haemostatix Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Haemostatix Limited's pipeline products

Reasons to buy

  • Evaluate Haemostatix Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Haemostatix Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Haemostatix Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Haemostatix Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Haemostatix Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Haemostatix Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Haemostatix Limited Snapshot
    • Haemostatix Limited Overview
    • Key Information
    • Key Facts
  • Haemostatix Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Haemostatix Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Haemostatix Limited - Pipeline Products Glance
    • Haemostatix Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Haemostatix Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Haemostatix Limited - Drug Profiles
    • PeproStat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HaemoPlax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HXTC-901
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Haemostatix Limited - Pipeline Analysis
  • Haemostatix Limited - Pipeline Products by Target
  • Haemostatix Limited - Pipeline Products by Route of Administration
  • Haemostatix Limited - Pipeline Products by Molecule Type
  • Haemostatix Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Haemostatix Limited, Key Information
  • Haemostatix Limited, Key Facts
  • Haemostatix Limited - Pipeline by Indication, 2015
  • Haemostatix Limited - Pipeline by Stage of Development, 2015
  • Haemostatix Limited - Monotherapy Products in Pipeline, 2015
  • Haemostatix Limited - Phase I, 2015
  • Haemostatix Limited - Preclinical, 2015
  • Haemostatix Limited - Discovery, 2015
  • Haemostatix Limited - Pipeline by Target, 2015
  • Haemostatix Limited - Pipeline by Route of Administration, 2015
  • Haemostatix Limited - Pipeline by Molecule Type, 2015

List of Figures

  • Haemostatix Limited - Pipeline by Top 10 Indication, 2015
  • Haemostatix Limited - Pipeline by Stage of Development, 2015
  • Haemostatix Limited - Monotherapy Products in Pipeline, 2015
  • Haemostatix Limited - Pipeline by Top 10 Target, 2015
  • Haemostatix Limited - Pipeline by Top 10 Route of Administration, 2015
  • Haemostatix Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top